Sickle Cell Disease
Sickle Cell Disease
Advertisement
Keightley Amen, BA, ELSSickle Cell Disease | June 18, 2025
Evidence was presented at EHA2025 that the agent improves RBC health and blood flow in patients.
Keightley Amen, BA, ELSSickle Cell Disease | June 17, 2025
Two cases of patients with SCD and history of delayed hemolytic transfusion reaction were presented at EHA2025.
Keightley Amen, BA, ELSSickle Cell Disease | June 17, 2025
The analysis was an assessment of 15-year follow-up data from the CLIMB study and was presented at EHA2025.
Melissa BadamoSickle Cell Disease | June 13, 2025
Vivien Sheehan, MD, explained how a novel assay can guide personalized therapeutic approaches for sickle cell disease.
Melissa BadamoSickle Cell Disease | June 11, 2025
Rilzabrutinib significantly decreased spleen weight and reduced inflammation in mice with homozygous sickle cell genotype.
Melissa BadamoSickle Cell Disease | June 10, 2025
MIRCA is a device designed to assess the flexibility of red blood cells of patients with sickle cell disease.
Melissa BadamoSickle Cell Disease | May 7, 2025
Compared with placebo, crizanlizumab has superior safety and comparable efficacy in patients with sickle cell disease.
Paul George, MD, PhDSickle Cell Disease | May 8, 2025
The study led by Paul George, MD, PhD, also highlights the importance of patient regimen adherence to secure these benefits.
Andrew MorenoSickle Cell Disease | April 29, 2025
The findings coincide with patient reports of experiencing increased vaso-occlusive episodes during menses.
Melissa BadamoSickle Cell Disease | April 22, 2025
The Foundation for Sickle Cell Disease Research will evaluate VAS-101 in a phase 1 clinical study.
Andrew MorenoSickle Cell Disease | April 8, 2025
The platform features incubation technology able to replicate cell microenvironments associated with SCD sickling.
Andrew MorenoSickle Cell Disease | February 19, 2025
Patients with follow-up of one month or longer saw hemolysis marker improvement and reported no vaso-occlusive crises.
Andrew MorenoSickle Cell Disease | February 18, 2025
In a phase III trial 90% of evaluable patients were free of severe vaso-occlusive crisis for at least 12 consecutive months.
Melissa BadamoSickle Cell Disease | February 13, 2025
Reni-cel led to hemoglobin normalization and increased fetal hemoglobin in patients with sickle cell disease.
Michael DeBaun, MD, MPHSickle Cell Disease | February 18, 2025
An expert panel's review finds SCT has often been misattributed as the direct cause of mortality in patients who have SCT.
Andrew MorenoSickle Cell Disease | January 23, 2025
Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Andrew MorenoASH 2024 | January 16, 2025
In a study SCT appeared linked to an increased risk of pregnancy-associated VTE, pulmonary embolism, and isolated DVT.
Melissa BadamoSickle Cell Disease | January 16, 2025
Patients receiving mitapivat showed a statistically significant hemoglobin response rate compared with placebo.
Andrew MorenoSickle Cell Disease | January 7, 2025
A review article describes current clinical knowledge of the role of inflammation and the activity of immune cells in SCD.
Nichole TuckerSickle Cell Disease | January 2, 2025
A study's efficacy and safety findings show promise for lovo-cel as a one-time intervention for SCD with history of stroke.
Advertisement